High‐dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

Previous controlled trials are inconclusive regarding the efficacy of ursodeoxycholic acid (UDCA) for treating primary sclerosing cholangitis (PSC). One hundred fifty adult patients with PSC were enrolled in a long‐term, randomized, double‐blind controlled trial of high‐dose UDCA (28‐30 mg/kg/day) versus placebo. Liver biopsy and cholangiography were performed before randomization and after 5 years. The primary outcome measures were development of cirrhosis, varices, cholangiocarcinoma, liver transplantation, or death. The study was terminated after 6 years due to futility. At enrollment, the UDCA (n = 76) and placebo (n = 74) groups were similar with respect to sex, age, duration of disease, serum aspartate aminotransferase and alkaline phosphatase levels, liver histology, and Mayo risk score. During therapy, aspartate aminotransferase and alkaline phosphatase levels decreased more in the UDCA group than the placebo group (P < 0.01), but improvements in liver tests were not associated with decreased endpoints. By the end of the study, 30 patients in the UDCA group (39%) versus 19 patients in the placebo group (26%) had reached one of the pre‐established clinical endpoints. After adjustment for baseline stratification characteristics, the risk of a primary endpoint was 2.3 times greater for patients on UDCA than for those on placebo (P < 0.01) and 2.1 times greater for death, transplantation, or minimal listing criteria (P = 0.038). Serious adverse events were more common in the UDCA group than the placebo group (63% versus 37% [P < 0.01]). Conclusion: Long‐term, high‐dose UDCA therapy is associated with improvement in serum liver tests in PSC but does not improve survival and was associated with higher rates of serious adverse events. (HEPATOLOGY 2009.)

[1]  J. Talwalkar,et al.  Tacrolimus for the treatment of primary sclerosing cholangitis , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[2]  E. Björnsson,et al.  Cholangiocarcinoma in Young Individuals With and Without Primary Sclerosing Cholangitis , 2007, The American Journal of Gastroenterology.

[3]  R. Chapman,et al.  High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. , 2006, Journal of hepatology.

[4]  D. Rockey,et al.  Noninvasive measures of liver fibrosis , 2006, Hepatology.

[5]  K. Boberg,et al.  High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. , 2005, Gastroenterology.

[6]  M. Färkkilä,et al.  Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo‐controlled trial , 2004, Hepatology.

[7]  A. Sanyal,et al.  A prospective, randomized‐controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis , 2004, Alimentary pharmacology & therapeutics.

[8]  D. Rost,et al.  Effect of high‐dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis , 2004, Hepatology.

[9]  K. Lindor,et al.  Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis , 2004, American Journal of Gastroenterology.

[10]  T. Therneau,et al.  Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. , 2003, Gastroenterology.

[11]  M. Colombo,et al.  Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[12]  F. Lammert,et al.  Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. , 2002, Gastroenterology.

[13]  Thore Egeland,et al.  Time‐dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis , 2002, Hepatology.

[14]  R. Chapman,et al.  A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. , 2001, Gastroenterology.

[15]  J. Talwalkar,et al.  Natural history and prognostic models in primary sclerosing cholangitis. , 2001, Best practice & research. Clinical gastroenterology.

[16]  W. Kremers,et al.  Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. , 2001, Gastroenterology.

[17]  W. Hop,et al.  No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study , 2001, European journal of gastroenterology & hepatology.

[18]  M. Kimmey,et al.  Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis , 2001, Annals of Internal Medicine.

[19]  A. Saven,et al.  An Open-label Pilot Trial of Cladibrine (2-Chlorodeoxyadenosine) in Patients with Primary Sclerosing Cholangitis , 2000 .

[20]  N. LaRusso,et al.  A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. , 2000 .

[21]  K. Batts,et al.  Oral budesonide in the treatment of primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.

[22]  W. Hop,et al.  Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study , 2000, American Journal of Gastroenterology.

[23]  C. Benz,et al.  [Primary sclerosing cholangitis]. , 2000, Der Internist.

[24]  N. LaRusso,et al.  High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.

[25]  T. Therneau,et al.  Time course of histological progression in primary sclerosing cholangitis. , 1999 .

[26]  T. Therneau,et al.  The relative role of the child‐pugh classification and the mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis , 1999, Hepatology.

[27]  T. Therneau,et al.  Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. , 1999, Journal of hepatology.

[28]  T. Therneau,et al.  Long‐term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis , 1999, Hepatology.

[29]  W. Hop,et al.  Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. , 1998, Journal of hepatology.

[30]  C. Steer,et al.  A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. , 1998, The Journal of clinical investigation.

[31]  N. LaRusso,et al.  Oral nicotine in the treatment of primary sclerosing cholangitis: A pilot study , 1998 .

[32]  E. Dickson,et al.  Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. , 1997, Gastroenterology.

[33]  A. di Sario,et al.  Cytotoxicity of bile salts against biliary epithelium: A study in isolated bile ductule fragments and isolated perfused rat liver , 1997, Hepatology.

[34]  K. Shetty,et al.  The Child‐Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis , 1997, Hepatology.

[35]  K. Lindor.  Ursodiol for Primary Sclerosing Cholangitis , 1997 .

[36]  T. Therneau,et al.  A revised natural history model for primary sclerosing cholangitis. , 1997, Mayo Clinic proceedings.

[37]  D. V. van Thiel,et al.  Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. , 1996, Hepato-gastroenterology.

[38]  A. Giunta,et al.  Ursodeoxycholic acid for liver disease associated with cystic fibrosis: A double‐blind multicenter trial , 1996, Hepatology.

[39]  T. Therneau,et al.  Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. , 1996, Gastroenterology.

[40]  Å. Danielsson,et al.  Colchicine treatment of primary sclerosing cholangitis. , 1995, Gastroenterology.

[41]  S. Ichihara,et al.  Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid. , 1994, Hepato-gastroenterology.

[42]  P. Gane,et al.  Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. , 1994, Gastroenterology.

[43]  E. Dickson,et al.  Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. , 1994, Gastroenterology.

[44]  M. Kaplan,et al.  A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. , 1994, Gastroenterology.

[45]  R. Wiesner,et al.  Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. , 1993, Gut.

[46]  P. Grambsch,et al.  Primary sclerosing cholangitis: refinement and validation of survival models. , 1992, Gastroenterology.

[47]  A. Giunta,et al.  Ursodeoxycholic acid therapy in cystic fibrosis—associated liver disease: A dose‐response study , 1992, Hepatology.

[48]  T. Sauerbruch,et al.  Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo‐controlled trial , 1992, Hepatology.

[49]  Y. Matsumura,et al.  Immunomodulatory effects of ursodeoxycholic acid on immune responses , 1992, Hepatology.

[50]  A. Giunta,et al.  Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease , 1992, Hepatology.

[51]  J. Senior,et al.  Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30‐month pilot study , 1991, Hepatology.

[52]  K. Kitani,et al.  Hepatic injury induced by bile salts: Correlation between biochemical and morphological events , 1990, Hepatology.

[53]  P. Galle,et al.  Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes , 1990, Hepatology.

[54]  K. Setchell,et al.  Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. , 1990, The Journal of pediatrics.

[55]  C. Colombo,et al.  Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration , 1990, Hepatology.

[56]  S. Katz,et al.  Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment. , 1989, Journal of lipid research.

[57]  P. Grambsch,et al.  Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis , 1989, Hepatology.

[58]  A. Zinsmeister,et al.  Prospective trial of penicillamine in primary sclerosing cholangitis. , 1988, Gastroenterology.

[59]  J. Lennard-jones,et al.  FAECAL BILE ACIDS, DYSPLASIA, AND CARCINOMA IN ULCERATIVE COLITIS , 1987, The Lancet.

[60]  M. Kaplan,et al.  A Pilot Study of Etanercept in the Treatment of Primary Sclerosing Cholangitis , 2004, Digestive Diseases and Sciences.

[61]  K. Lindor.  Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. , 1997, The New England journal of medicine.

[62]  D. V. van Thiel,et al.  Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. , 1995, The American journal of gastroenterology.

[63]  D. V. van Thiel,et al.  Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. , 1995, The American journal of gastroenterology.

[64]  W. Hofmann,et al.  Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. , 1994, Journal of hepatology.

[65]  R. Wiesner,et al.  The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. , 1991, The American journal of gastroenterology.